Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2020 3
2021 3
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
Berdel AF, Schwöppe C, Brand C, Harrach S, Brömmel K, Hintelmann H, Lenz G, Liersch R, Heinzow H, Schliemann C, Mesters RM, Berdel WE, Kessler T. Berdel AF, et al. Cancers (Basel). 2021 Jun 7;13(11):2841. doi: 10.3390/cancers13112841. Cancers (Basel). 2021. PMID: 34200318 Free PMC article. Review.
Bridging of membrane surfaces by annexin A2.
Grill D, Matos ALL, de Vries WC, Kudruk S, Heflik M, Dörner W, Mootz HD, Jan Ravoo B, Galla HJ, Gerke V. Grill D, et al. Sci Rep. 2018 Oct 2;8(1):14662. doi: 10.1038/s41598-018-33044-3. Sci Rep. 2018. PMID: 30279443 Free PMC article.
Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
Berdel WE, Harrach S, Brand C, Brömmel K, Berdel AF, Hintelmann H, Schliemann C, Schwöppe C. Berdel WE, et al. Cancers (Basel). 2020 Nov 26;12(12):3536. doi: 10.3390/cancers12123536. Cancers (Basel). 2020. PMID: 33256235 Free PMC article.
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE. Schliemann C, et al. Cancers (Basel). 2020 Jun 7;12(6):1488. doi: 10.3390/cancers12061488. Cancers (Basel). 2020. PMID: 32517329 Free PMC article.
11 results